Shares were up slightly to $86.84 in trading Tuesday.
The company reported net income of $2 billion, or $1.41 a share, up from $1.88 billion, or $1.22 a share, a year ago, beating Wall Street's forecast for $1.32 a share.
Sales totaled $12.2 billion, up 10% from a year ago, and ahead of analysts' expectations of $11.7 billion. The increase was driven mainly from sales of the psoriasis treatment Cosentyx, the cardiovascular drug Entresto, the gene therapy treatment Zolgensma for spinal muscular atrophy, and the acquisition of Xiidra, a dry eye medication.
Zolgensma sales totaled $160 million, well ahead of the consensus call for $102.6 million. In August, the U.S. Food & Drug Administration said that some data from the testing of Zolgensma had been manipulated, but maintained the drug should stay on the market.
At roughly $2.1 million per patient, Zolgensma has been called the most expensive treatment on the market.
Core operating profit totaled $3.75 billion, up from $3.26 billion a year ago.
For 2019, the company said it expects sales to grow by a high single-digit percentage at constant currency, while core operating income is expected to grow to mid- to high-teens.
Save 57% during our Halloween Sale. Don't let this market haunt you and join Jim Cramer's Investment Club, Action Alerts PLUS. Click here to sign up!